Effectiveness of Pharmaceutical Smoking Cessation Aids in a Nationally Representative Cohort of American Smokers
Authors:
Open Access
- 21 December 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 110 (6) , 581-587
Abstract
Despite strong efficacy in randomized trials, the population effectiveness of pharmaceutical aids in long-term smoking cessation is lacking, possibly because of confounding (factors that are associated with both pharmaceutical aid use and difficulty quitting). Matching techniques in longitudinal studies can remove this confounding bias. Using the nationally representative Tobacco Use Supplement to the Current Population Survey (TUS-CPS), we assessed the effectiveness of medications to aid quitting among baseline adult smokers who attempted to quit prior to one year of follow-up in two longitudinal studies: 2002–2003 and 2010–2011. Pharmaceutical aid users and nonusers with complete data (n = 2129) were matched using propensity score models with 12 potential confounders (age, sex, race-ethnicity, education, smoking intensity, nicotine dependence, previous quit history, self-efficacy to quit, smoke-free homes, survey year, and cessation aid use). Using matched data sets, logistic regression models were fit to assess whether use of any individual pharmaceutical aid increased the proportion of patients who were abstinent for 30 days or more at follow-up. Propensity score matching markedly improved balance on the potential confounders between the pharmaceutical aid use groups. Using matched samples to provide a balanced comparison, there was no evidence that use of varenicline (adjusted risk difference [aRD] = 0.01, 95% confidence interval [CI] = –0.07 to 0.11), bupropion (aRD = 0.02, 95% CI = –0.04 to 0.09), or nicotine replacement (aRD = 0.01, 95% CI = –0.03 to 0.06) increased the probability of 30 days or more smoking abstinence at one-year follow-up. The lack of effectiveness of pharmaceutical aids in increasing long-term cessation in population samples is not an artifact caused by confounded analyses. A possible explanation is that counseling and support interventions provided in efficacy trials are rarely delivered in the general population.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (T32HL007034)
This publication has 32 references indexed in Scilit:
- The Effects of Smoking-Related Television Advertising on Smoking and Intentions to Quit Among Adults in the United States: 1999–2007American Journal of Public Health, 2012
- Interventions to increase smoking cessation at the population level: how much progress has been made in the last two decades?Tobacco Control, 2012
- An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational StudiesMultivariate Behavioral Research, 2011
- Causation and Causal Inference2011
- The Use of Propensity Scores to Assess the Generalizability of Results from Randomized TrialsJournal of the Royal Statistical Society Series A: Statistics in Society, 2010
- A Clinical Practice Guideline for Treating Tobacco Use and Dependence: 2008 UpdateAmerican Journal of Preventive Medicine, 2008
- Smoking Cessation Rates in the United States: A Comparison of Young Adult and Older SmokersAmerican Journal of Public Health, 2008
- Time to first cigarette in the morning as an index of ability to quit smoking: Implications for nicotine dependenceNicotine & Tobacco Research, 2007
- Is nicotine replacement therapy for smoking cessation effective in the "real world"? Findings from a prospective multinational cohort studyThorax, 2007
- Estimating causal effects from epidemiological dataJournal of Epidemiology and Community Health, 2006